Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Medical Oncology (Northwood, London, England)|November 28, 2007
Acute lymphoblastic leukemia during gestationCharis Matsouka, Spyridon Marinopoulos, Despina Barbaroussi, et al.
Clinical Lymphoma|January 8, 2005
Hemophagocytic lymphohistiocytosis after chemotherapy for multiple myelomaJohn V Terrovitis, Charis Matsouka, Athanassios Anagnostopoulos, et al.
Leukemia & Lymphoma|April 25, 2007
Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: long term follow up and disease control after subsequent treatmentsMaria Roussou, Athanasios Anagnostopoulos, Efstathios Kastritis, et al.
Annals of Vascular Surgery|October 13, 2021
Multiple Sites of Arterial Thrombosis in A 35-Year Old Patient after ChAdOx1 (AstraZeneca) Vaccination, Requiring Emergent Femoral and Carotid Surgical ThrombectomyStella Lioudaki, Nikolaos Kontopodis, Charalampos Pontikoglou, et al.
Leukemia & Lymphoma|June 30, 2004
The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemiaMeletios Dimopoulos, Dimitra Gika, Konstantinos Zervas, et al.
Leukemia & Lymphoma|May 9, 2008
Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimensMaria Roussou, Efstathios Kastritis, Magdalini Migkou, et al.
Haematologica|May 10, 2007
Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agentsEfstathios Kastritis, Athanasios Anagnostopoulos, Maria Roussou, et al.
Leukemia & Lymphoma|July 12, 2003
Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamideMeletios A Dimopoulos, George Hamilos, Eleni Efstathiou, et al.
European Journal of Haematology|June 3, 2011
Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapyMagdalini Migkou, Efstathios Kastritis, Maria Roussou, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 10, 2011
Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myelomaMaria Gkotzamanidou, Efstathios Kastritis, Maria Roussou Magdalini Migkou Maria Gavriatopoulou, et al.
Pageof 3